Tests (units)/dates | 08/24–26 | 09/02 | 11/18 | Reference range |
---|---|---|---|---|
Hemoglobin (g/dL) | 12.8 | 10.7 | 12.9 | 11.5–13.5 |
Leukocytes (cells/mm3) | 10,030 | 8450 | 6170 | 5000–14,500 |
Platelets (cells/mm3) | 369,000 | 589,000 | 432,000 | 150,000–400,000 |
C-Reactive protein (mg/L) | 233 | 62 | – | < 12 |
Aspartate aminotransferase (IU/L) | 326 | 48 | 33 | 10–47 |
Alanine aminotransferase (IU/L) | 234 | 49 | 19 | 24–49 |
Bilirubin/direct bilirubin (mg/dL) | 4.4/4.0 | 0.9/0.6 | 0/0 | ≤ 1.2/≤ 0.4 |
Gamma-glutamyl transferase (IU/L) | 833 | 239 | 22 | < 30 |
Alkaline phosphatase (IU/L) | 770 | 329 | 253 | 142–335 |
Albumin (g/dL) | 3.9 | 3.9 | 4.3 | 2.9–4.7 |
Activated partial thromboplastin time (s) | 69 | 62 | 77 | 25–35 |
International normalized ratio (INR) | 1.28 | 1.38 | 1.3 | 0.87–1.2 |
D-dimer (mcg/mL) | 1.46 | 1.83 | – | ≤ 0.5 |
α1-Antitrypsin (mg/L) | 293 | – | – | 78–200 |
Ceruloplasmin (mg/dL) | 36 | – | – | 20–60 |
Antinuclear antibody | 1:80 | – | – | NR |
Anti-smooth muscle | NR | – | – | NR |
Seric copper (mcg/dL) | 177 | – | – | 90–190 |
Urinary copper (mcg/24 hs) | 11 | – | – | ≤ 60 |
Anti-liver kidney microsome type 1 | – | NR | – | NR |
SARS-CoV-2 IgG/IgA/IgM | P/P/P | – | – | N |
VDRL | N | – | – | N |
RTqPCR influenza A, B; RSV and SARS-CoV2 | N/N/N | – | – | N/N/N |
Anti-human immunodeficiency virus 1,2 | N | – | – | N |
Anti-hepatitis A virus/C virus | N/N | – | – | N/N |
Anti-hepatitis E IgM | N | – | – | N |
Hepatitis B, HBsAg, anti-HBc-IgM | N/N/N | – | – | N/N/N |
Anti-human herpes virus IgM | N | – | – | N |
Anti-cytomegalovirus IgG/IgM | P/N | – | – | N |
Anti-Epstein–Barr virus IgG/IgM | P/N | – | – | N |
TLR-7 T/T (A/A) | – | – | M | – |
TLR-3 C/C (C/C) | – | – | NH | - |
TIRAP C/C (C/C) | – | – | NH | – |
MCP-1 A/A (A/A) | – | – | NH | – |
OAS-3 C/C (C/C) | – | – | NH | – |